No Picture
News

Catalyst Biosciences Announces Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors

SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company that is developing novel subcutaneous (SQ) therapies for hemophilia and other inherited bleeding disorders, today a… […]

No Picture
News

Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the European Association for Haemophilia and Allied Disor… […]

No Picture
News

Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the app… […]

No Picture
News

Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the 2019 American Society for Biochemistry and Molecular Biology (ASBMB) Symposium on Serine Proteases … […]